Literature DB >> 11033107

Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.

B D Walker1, C B Singleton, H Tie, J A Bursill, K R Wyse, S M Valenzuela, S N Breit, T J Campbell.   

Abstract

OBJECTIVE: To evaluate the effects of azimilide and ambasilide on the biophysical properties of the human-ether-a-go-go-related (HERG) channel.
METHODS: HERG was stably transfected into Chinese hamster ovary (CHO-K1) cells and currents were measured using a whole cell, voltage-clamp technique.
RESULTS: Azimilide had a 'dual effect', inhibiting current at voltage steps above -40 mV and augmenting current at -40 and -50 mV. Tail current inhibition following a step to +30 mV did not vary with temperature (IC(50) 610 nM at 22 degrees C and 560 nM at 37 degrees C). The agonist effect at -50 mV was concentration-dependent and correlated with a hyperpolarizing shift in the V(1/2) of activation (r=0.98, P<0.05). Time constants of inactivation were faster and there was a -10 mV shift in the V(1/2) of steady state inactivation suggestive of open and inactivated state binding. By comparison, ambasilide inhibited HERG channels with lower potency (IC(50) 3.6 microM), in a voltage- and time-dependent but frequency-independent manner (0.03-1 Hz). Ambasilide had no effect on activation or inactivation gating but prolonged both fast and slow components of deactivation consistent with unbinding from the open state. The net effect of both drugs was similar during a voltage ramp which simulated a cardiac action potential.
CONCLUSIONS: Inhibition of HERG channels by azimilide and ambasilide exhibits a similar time and voltage-dependence. While both exhibit affinity for the open state, azimilide also binds to inactivated channels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033107     DOI: 10.1016/s0008-6363(00)00155-3

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

1.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

2.  Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.

Authors:  Eberhard P Scholz; Edgar Zitron; Claudia Kiesecker; Sonja Lück; Dierk Thomas; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Johann Kiehn; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-09       Impact factor: 3.000

3.  A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.

Authors:  Zhihua Li; Sara Dutta; Jiansong Sheng; Phu N Tran; Wendy Wu; Thomas Colatsky
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-11       Impact factor: 1.950

4.  The Effectiveness of Isoplumbagin and Plumbagin in Regulating Amplitude, Gating Kinetics, and Voltage-Dependent Hysteresis of erg-mediated K+ Currents.

Authors:  Linyi Chen; Hsin-Yen Cho; Tzu-Hsien Chuang; Ting-Ling Ke; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2022-03-27

5.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

6.  The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Authors:  Q Tang; Z-Q Li; W Li; J Guo; H-Y Sun; X-H Zhang; C-P Lau; H-F Tse; S Zhang; G-R Li
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

7.  Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.

Authors:  Ashok A Paul; Harry J Witchel; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

8.  Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome.

Authors:  Harinath Sale; Jinling Wang; Thomas J O'Hara; David J Tester; Pallavi Phartiyal; Jia-Qiang He; Yoram Rudy; Michael J Ackerman; Gail A Robertson
Journal:  Circ Res       Date:  2008-09-05       Impact factor: 17.367

9.  Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.

Authors:  Sungpil Han; Seunghoon Han; Ki-Suk Kim; Hyang-Ae Lee; Dong-Seok Yim
Journal:  Front Pharmacol       Date:  2019-11-26       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.